Aspirin has been postulated to exert a dose dependent, selective inhibition of thromboxane synthesis. We propose to compare the effects of acute and chronic administration of a wide range of aspirin doses on prostanoid generation and platelet function. In particular, we shall focus on the recovery of prostacyclin biosynthesis following aspirin as our preliminary data indicates prolonged suppression after chronic dosing. Aspirin is rapidly converted to salicylate in vivo and salicylate prevents inhibition of platelet thrombosane synthesis by aspirin in vitro. Thus, we also propose to assess the effects of sodium salicylate on endogenous prostanoid generation and the effects of salicylate consumption on aspirin inhibition of prostanoid generation in man. Novel synthesis of a deuterated derivative of aspirin will permit us to relate the pharmacokinetics of a range of aspirin doses to their pharmacodynamic effects and to characterize the potential interactions of aspirin and dipyridamole, two antiplatelet agents often used in combination in clinical practice. In vitro sulfinpyrazone inhibits platelet cyclooxygenase and platelet aggragation. The influence of sulfinpyrazone upon biosynthesis in man is unknown and in vitro studies suggest that metabolites, rather than the parent compound may mediate its antiplatelet effects in vivo. We propose to relate the pharmacokinetics of sulfinpyrazone and its metabolites during acute and chronic dosing to platelet function, and prostanoid production in man. Selective inhibition of thromboxane synthesis would be theoretically attractive, in that depression of prostacyclin synthesis would not occur as with cyclooxygenase inhibitors such as aspirin. We shall test the functional importance of such selectivity by a controlled comparison of the effects of such an inhibitor, dazoxiben, with high and low dose aspirin on indices of venous graft obstruction in patients with peripheral vascular disease. Such a study will also clarify whether diversion of endoperoxide metabolism towards increased biosynthesis of other prostanoids occurs during therapy with a thrombozane synthase inhibitor. Substantial resource has been devoted to clinical trials of antiplatelet drug with inconclusive results. By clarifying their clinical pharmacology, the proposed studies will permit more rational evaluation of these agents in the future.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL030400-04
Application #
3341428
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1983-04-01
Project End
1987-11-30
Budget Start
1986-04-01
Budget End
1987-11-30
Support Year
4
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Pratico, D; O'Mahony, D; Lawson, J et al. (1997) Cellular activation by thromboxane A2 and 8-EPI-PGF2 alpha. Adv Exp Med Biol 400A:229-33
Murphy, R C; FitzGerald, G A (1994) Current approaches to estimation of eicosanoid formation in vivo. Adv Prostaglandin Thromboxane Leukot Res 22:341-8
Sorensen, J D; Olsen, S F; Pedersen, A K et al. (1993) Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production. Am J Obstet Gynecol 168:915-22
Funk, C D (1993) Molecular biology in the eicosanoid field. Prog Nucleic Acid Res Mol Biol 45:67-98
Funk, C D; Furci, L; Moran, N et al. (1993) Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharmacol 44:934-9
Funk, C D; Furci, L; FitzGerald, G A et al. (1993) Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem 268:26767-72
Remuzzi, G; FitzGerald, G A; Patrono, C (1992) Thromboxane synthesis and action within the kidney. Kidney Int 41:1483-93
FitzGerald, G A; Shipp, E (1992) Antiplatelet and anticoagulant drugs in coronary vascular disease. Ann Epidemiol 2:529-42
Funk, C D; Funk, L B; FitzGerald, G A et al. (1992) Characterization of human 12-lipoxygenase genes. Proc Natl Acad Sci U S A 89:3962-6
Kunitada, S; FitzGerald, G A; Fitzgerald, D J (1992) Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 79:1420-7

Showing the most recent 10 out of 95 publications